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Abstract
Background: The relationship between health professionals and the pharmaceutical industry has become a source of
controversy. Physicians’ attitudes towards the industry can form early in their careers, but little is known about this key
stage of development.
Methods and Findings: We performed a systematic review reported according to PRISMA guidelines to determine the
frequency and nature of medical students’ exposure to the drug industry, as well as students’ attitudes concerning
pharmaceutical policy issues. We searched MEDLINE, EMBASE, Web of Science, and ERIC from the earliest available dates
through May 2010, as well as bibliographies of selected studies. We sought original studies that reported quantitative or
qualitative data about medical students’ exposure to pharmaceutical marketing, their attitudes about marketing practices,
relationships with industry, and related pharmaceutical policy issues. Studies were separated, where possible, into those
that addressed preclinical versus clinical training, and were quality rated using a standard methodology. Thirty-two studies
met inclusion criteria. We found that 40%–100% of medical students reported interacting with the pharmaceutical industry.
A substantial proportion of students (13%–69%) were reported as believing that gifts from industry influence prescribing.
Eight studies reported a correlation between frequency of contact and favorable attitudes toward industry interactions.
Students were more approving of gifts to physicians or medical students than to government officials. Certain attitudes
appeared to change during medical school, though a time trend was not performed; for example, clinical students (53%–
71%) were more likely than preclinical students (29%–62%) to report that promotional information helps educate about
new drugs.
Conclusions: Undergraduate medical education provides substantial contact with pharmaceutical marketing, and the
extent of such contact is associated with positive attitudes about marketing and skepticism about negative implications of
these interactions. These results support future research into the association between exposure and attitudes, as well as any
modifiable factors that contribute to attitudinal changes during medical education.
Please see later in the article for the Editors’ Summary.
Citation: Austad KE, Avorn J, Kesselheim AS (2011) Medical Students’ Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review. PLoS
Med 8(5): e1001037. doi:10.1371/journal.pmed.1001037
Academic Editor: Joel Lexchin, York University, Canada
Received November 9, 2010; Accepted April 15, 2011; Published May 24, 2011
Copyright:  2011 Austad et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Study funded by a grant from the Edmond J. Safra Center for Ethics at Harvard University. Dr. Kesselheim is supported by a career development award
from the Agency for Healthcare Research & Quality (K08HS18465-01), and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: KEA reports employment by the USMLE preparation company USMLERx to write content question for their Step 1 question bank and is a
3rd year medical student at Harvard Medical School and a lab fellow at the Edmond J. Safra Center for Ethics at Harvard University and a member of the Division
of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital.
Abbreviations: OR, odds ratio; PSR, pharmaceutical sales representative
* E-mail: akesselheim@partners.org
PLoS Medicine | www.plosmedicine.org 1 May 2011 | Volume 8 | Issue 5 | e1001037Introduction
The relationship between physicians and the pharmaceutical
industry has become a major topic of concern for health services
researchers [1] and policymakers [2], as well as in the lay media.
While opinions about such relationships vary [3–6], it is clear that
physicians have a high level of exposure to industry marketing in a
variety of forms, which impacts clinical decision making [4].
Industry involvement in medical education occurs on multiple
levels, including one-on-one meetings between trainees and
pharmaceutical sales representatives (PSRs) and sponsored
publications and educational events (such as Continuing Medical
Education courses). Because pharmaceutical companies recognize
the potential for education to be used as a marketing tool [7,8],
there is concern that such exposure may communicate a biased
message encouraging overuse of particular products [9,10].
Interactions with PSRs can increase prescriptions of the drug
being promoted and shift prescribing in ways that may not be
consistent with evidence-based guidelines [11–13]. One common
outcome is the use of expensive treatments without therapeutic
advantage over less costly alternatives [4,14,15]. Industry-
sponsored education may also influence physicians’ ability to
weigh the risk-benefit profiles of new, heavily promoted drugs.
For example, in the case of rofecoxib (Vioxx), pharmaceutical
manufacturer–sponsored educational materials downplayed the
drug’s cardiac risks (a nearly 2-fold increased risk of heart attack
and stroke) [16].
Why does pharmaceutical industry marketing have such a
substantial effect on physician behavior [17]? One explanation
may be that physicians’ attitudes towards the industry and their
propensity to be influenced by its marketing form very early in
their careers. The socialization effect of professional schooling is
strong [18–20], and plays a lasting role in shaping students’ views
and behaviors [21]. For example, a study examining the behavior
of physicians trained in residency programs that limit contact
with PSRs found that such policies shape subsequent decision
making [22]. Therefore, encouraging more rational prescribing
among practicing physicians may require a better understanding
of how medical students interact with the pharmaceutical
industry.
Moves to limit industry influence on undergraduate medical
education have been contentious. In recent years, medical schools
have taken proactive steps to limit students’ and faculties’ contact
with industry [23]. These steps have included instituting guidelines
for speaking and consulting relationships and mandating faculty
disclosure of potential conflicts of interest on a public website
[24,25]. However, some have argued that these restrictions are
detrimental to students’ education and the future of biomedical
research [26,27].
Given the controversy over the pharmaceutical industry’s role
in undergraduate medical training, synthesizing the current
state of knowledge is useful for setting priorities for changes to
educational practices and the establishment of a research
agenda. We systematically examined the peer-reviewed litera-
ture through May 2010 to collect empirical data quantifying
medical students’ exposure to and perspectives on pharmaceu-
tical marketing practices, including their behaviors related to
prescribing and attitudes about important drug policy topics.
Specifically, we examined the extent of pharmaceutical industry
interactions with medical students, whether such interactions
influenced students’ views on related topics, and whether any
differences exist between students in their preclinical versus
clinical years or in different learning environments in relation to
these issues.
Methods
Data Sources and Searches
We searched MEDLINE (PubMed), EMBASE, Web of Science,
and ERIC (EBSCOHost) for peer-reviewed articles from the
earliest available dates through May 2010 with the help of a
medical librarian. For search terms, two main subject heading
domains were combined with the AND operator: one to designate
the population (e.g., ‘‘medical students’’) and the other to
designate the topics relevant to the research question (e.g.,
‘‘pharmaceutical industry’’ and ‘‘conflict of interest’’). A full list
of search terms is available in Table S1. Both Medical Subject
Heading (MeSH) terms (or equivalent) and free text were utilized.
No language requirement was placed on the search. Nine
additional abstracts not captured by the search strategy were
identified through review of the bibliographies of included articles.
Study Selection
We developed a screening strategy using three criteria. First,
studies were required to present data specific to medical students.
If a study did not indicate whether the year of the students
reflected clinical or preclinical training, this information was
obtained from descriptions of the medical curricula on the
institutional website(s) where the survey was conducted.
Second, studies had to include an observational or experimental
design and employ quantitative or qualitative methods. We
excluded editorials and other nonempirical opinion pieces. If the
study reported pretests and post-tests related to an educational
intervention, only preintervention data were analyzed (this
occurred in six studies).
Finally, studies were required to report data on either (a)
students’ exposures to pharmaceutical industry marketing (e.g.,
counts of meetings with PSRs, gifts, and attendance at industry-
sponsored educational events), or (b) students’ knowledge,
attitudes, and behaviors relating to industry, prescribing practices,
or pharmaceutical policy issues, including the educational value of
marketing materials, the costs of drug development or treatment
regimens, and generic drug use. We excluded studies reporting
students’ perspectives on complementary and alternative medi-
cines, use of specific therapeutic classes (such as antipsychotics),
and medical errors and safety as long as those studies did not also
examine industry marketing practices in relation to those topics.
Our screening criteria were applied separately in a pilot phase
by two authors (KEA and ASK) on a selection of 10% of the
pulled abstracts to ensure clarity of the criteria and reproducibility
of the results. Then, one of us (KEA) reviewed the entire list of
abstracts and identified articles for full review.
Data Extraction and Quality Assessment
We noted the study type and characteristics of the populations
studied, including year in medical school (preclinical versus
clinical), country, sample size, and response rate. Next, we
extracted primary data using a piloted extraction tool, including:
exposure to industry (type of interaction and frequency); student
attitudes about pharmaceutical marketing practices; views and
practices related to evidence-based prescribing; and perspectives
on use of generic drugs, drug development, and cost of treatment.
We identified any correlations between measures (such as exposure
and attitudes) and the methodology used to test the correlation.
Non-English language articles were translated by a native speaker.
We assessed quality of survey studies using the Glaser and Bero
protocol [28], a five-point scale for rating surveys based on study
population, generalizability, survey content and construction, and
data analysis. Other investigators have also used this strategy in
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authors (KEA and ASK) independently rated each study and
disagreements (which occurred in seven out of the 29 rated) were
resolved by consensus.
Data Synthesis and Analysis
Given the heterogeneity of studies, qualitative rather than
quantitative synthesis of data was performed. We sorted studies on
the basis of population training level: ‘‘preclinical’’ (defined as
predominantly classroom education), ‘‘clinical’’ (defined as pri-
marily clinical education, including clerkship), or ‘‘both.’’ Data
regarding student attitudes were grouped according to type of
marketing practice or industry relationship queried. We also
performed a sensitivity analysis to explore the effect of excluding
older studies (those performed before 2000) and those of lower
methodological strength (score 0–2) from our results. The funders
of the study played no role in the design of the study, data
interpretation, or manuscript preparation. The PRISMA flow-
chart is available in Text S1.
Results
Our search strategy produced 1,603 abstracts. We identified 48
articles for full review and confirmed 33 [30–62] as eligible for
analysis (Figure 1) [63]. Two papers [46,47] reported overlapping
data from the same sample of students, so we combined them for
an effective total of 32 studies. The vast majority of studies (29/32,
91%) [30–32,34–36,38–39,41–62] used a cross-sectional survey as
the primary methodology, occasionally supplemented with other
techniques, such as informant interviews [54] and analyses of
student journals [30]. The remaining study designs included a
practical exam [33], a case study [40], and a randomized
experiment [37]. In total, studies assessed approximately 9,850
medical students at 76 medical schools or hospitals (one study [49]
did not specify participants’ school affiliation). All studies reviewed
are listed in Table 1.
The studies included in this review were published between
1971 and 2010; however, only seven (7/32, 22%) were published
before 2000, and the majority of these (5/7, 71%) received a score
of 0, 1, or 2 for methodological quality. Over half assessed medical
students from the US (15/32, 47%) or Canada (4/32, 13%), but
Australia, Russia, and countries in Europe and the Middle East
were also represented. Nearly all employed a self-report cross-
sectional survey design; many employed additional qualitative
methodologies including free-text response, focus groups, and
analysis of student journal entries. Seventeen (53%) evaluated only
clinical students, five (16%) preclinical students, and ten (31%)
compared clinical and preclinical students. Sample sizes ranged
from 17 to 1,523. The median methodological quality score was 3
out of 5 (interquartile range=2–4).
Exposure to Pharmaceutical Marketing
Medical students reported frequently interacting with the
pharmaceutical industry (Table 2). Common types of interactions
include involved gifts [31,32,40,43,48–50,55,58], industry-spon-
sored educational sessions [43,53,57], and direct communications
with sales representatives [30,41,44,46,47,50,53,55,57]. We found
that 89%–98% of students in the clinical years reported having
accepted a lunch or snack provided by the pharmaceutical
industry [43,58]; one study of clinical students reporting on
interactions with PSRs reported that 90% of exchanges involved
food [41]. One multi-institution study from 2005 calculated that
third-year American medical students interacted with industry on
average once per week [43]. Up to 90% [41,43,49] of surveyed
students in their clinical years had received educational materials
such as textbooks or journal reprints from industry. Substantial
variability was noted between studies performed in different
countries, with the highest level of exposure occurring in the US,
including two studies [48,58] that found 100% of students had at
least one interaction.
Overall, contact with the pharmaceutical industry increased
over the course of medical school. This trend was observed both in
studies reporting cumulative incidence (total number of exposures
since starting medical school) in preclinical and clinical popula-
tions [30–32,35,38,44,48,49,55,58], as well as studies considering
exposure during a single academic year or per month [40,43,46,
47,50,53,57]. This increase was consistent across most of the types
of interactions listed in Table 2.
Attitudes about Marketing Practices
Students’ attitudes about pharmaceutical marketing practices
were variable and occasionally contradictory (Table 3). Many
students approved of meals [31,32,35,43,46,47,59], small promo-
tional items [32,43,46,48,59,62], and gifts with an educational
purpose [31,32,35,43,46–48,59], but were less accepting of social
events [31,32,43,61,62] and travel [31,32,35,43,46–48]. However,
75% of students in an Italian study said they would renounce gifts
from industry [54]. Students justified their entitlement to gifts by
citing financial hardship (48%–80%) [31,37,43] or by asserting
that most others accepted gifts [54].
When asked about the appropriateness of accepting gifts from
industry overall, students at different levels of training expressed
divergent opinions. In most studies, the majority of students in
their clinical training years found it ethically permissible for
medical students to accept gifts from drug manufacturers
[37,43,52,55,56], while a smaller percentage (28%–48%) of
preclinical students reported such attitudes [31,32,55,56]. This
same trend was seen in student opinion regarding whether
physicians should accept gifts [48,55]. Many students displayed
exceptionalism with regard to the medical profession, as
approximately 85% reported that it would be inappropriate for
a government official to accept similar gifts [52,55]. Two surveys
found no change in perceived appropriateness of gifts from
industry as students progressed in their training [32,34].
One of the most consistently held student attitudes was the belief
that education from industry sources is biased [32,37,43,44],
especially among clinical students (67%–92%) [37,43,44]. Despite
this, students variably reported (22%–89%) that information
obtained from industry sources was useful and a valuable part of
their education [30–32,35,37,43,44,46–48,50], with clinical stu-
dents more frequently endorsing the utility.
In most studies, almost two-thirds of students reported that they
were immune to bias induced by promotion [53,57], gifts
[31,32,37,43,46,47], or interactions with sales representatives in
general [46,47,54]. This perception of immunity to bias was
prevalent in both the preclinical and clinical years. It appeared
that students were more likely to report that fellow medical
students (38%–69%) or doctors (13%–71%) are influenced by such
encounters than they were personally (24%–63%) [31,37,43,
46,47,54].
Effect of Marketing Practices on Attitudes
Eight studies reported a relationship between exposure to the
pharmaceutical industry and positive attitudes about industry
interactions and marketing strategies (though not all included
supportive statistical data) [30,32,35,43,49,50,53,57]. In a national
survey, students’ overall level of exposure to pharmaceutical
marketing was inversely correlated with the attitude that these
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the belief that these educational sources were biased and
influenced prescribing (r=20.171; p,0.001) [43]. Students who
interacted with PSRs were more likely than those who did not
meet with PSRs to report positive perceptions of industry
marketing (odds ratio [OR]=2.974, p=0.012) and were less
likely to perceive this marketing as negative (OR=0.408,
p=0.004) [30]. Lea et al. found that degree of industry exposure
was associated with students’ attitudes that they had the ability to
self-regulate interactions with industry (31% versus 41% versus
Figure 1. PRISMA schematic of systematic review search process.
doi:10.1371/journal.pmed.1001037.g001
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First Author,
Year (Country)
Primary
Methodology
Response
Rate
Quality
Rating
(out of 5)
a Main Findings
Studies including
only preclinical
students
Sarikaya, 2009
(Turkey) [30]
Cross-sectional survey,
multi-institutional
308/398, 77% 3 91% students experienced industry marketing. Favorable attitudes toward
industry were more common for those who had interactions with PSRs (versus no
interaction, OR=2.974, p=0.012)
Fein, 2007
(US) [31]
Cross-sectional survey 226/288, 79% 4 77% students had received gifts by their third semester, 24% agreed that
accepting gifts would influence their future prescribing.
Ball, 2007
(Kuwait) [32]
Cross-sectional survey 103/299, 34% 3 70% reported that textbook is appropriate gift, 24% believed the same for meal.
74% believed that drug company presentations were biased.
Al Khaja, 2005
(Bahrain) [33]
Objective structured
practical exam
539 N/A 81% of drugs correctly prescribed by students were written with generic instead
of brand names
Vinson, 1993
(US) [34]
Cross-sectional survey
(preintervention)
156/215, 73% 3 No observed difference in acceptance of marketing between 1st and 2nd years
Studies including
only clinical
students
Lea, 2010
(Norway, Hungary,
Poland) [35]
Cross-sectional survey,
multi-institutional
819/1,245, 66% 4 74% students had contact with pharmaceutical industry. Exposure correlated with
self-perceived ability to handle industry interactions.
Tichelaar, 2009
(Netherlands) [36]
Cross-sectional survey,
multi-institutional
32/32, 100% 3 Students identified ‘‘effectiveness of the drugs’’ and ‘‘examples from medical
teachers’’ as the most important factors in determining treatment choice.
Grande, 2009
(US) [37]
Randomized experimental
design with follow-up sur
vey assessment,
multi-institutional
352 N/A Students from school with policy limiting industry interactions had significantly
less favorable attitudes about industry, including increased skepticism (mean
scaled score: 0.42 versus 0.55, p,0.001)
Markham, 2009
(US) [38]
Cross-sectional survey
(preintervention)
243 2 Around 95% reported that they accepted gifts from industry. Students estimated
that the average drug costs US$20–US$50 million to develop.
Volodina, 2009 (Russia,
Germany) [39]
Cross-sectional survey,
multi-institutional
226/240, 94% 3 Nearly all students agreed that corporate social responsibility should be important
for pharmaceutical industry
Tardif, 2009
(Canada) [40]
Case-study 17 N/A 23% students exposed to drug samples in previous year. 67% believed that
samples increased use of non–first-line treatments.
Straand, 2008
(Norway) [41]
Cross-sectional survey 144/241, 60%
(survey only)
4 Students most commonly received food (90%) and educational material (87%)
from PSR interactions.
Hassali, 2007
(Australia) [42]
Cross-sectional survey,
multi-institutional
400/1,497, 27% 4 Poor performance on test of criteria for generic drug bioequivalence. Respondents
reported that generics had lower safety standards, produced more side-effects,
and were less effective than brand-name drugs.
Sierles, 2005
(US) [43]
Cross-sectional survey,
multi-institutional
826/1,143, 72% 5 On average interacted with industry once per week. Exposure correlated positively
with acceptance and negatively with skepticism.
Wofford, 2005
(US) [44]
Cross-sectional survey
(preintervention)
75 3 87% believed PSR information was biased; 44% agreed that PSRs impacted
physician prescribing.
Stanley, 2005
(UK) [45]
Cross-sectional survey
(preintervention)
29 1 Mean score on drug development test was 33%. Majority agreed that ‘‘Results of
clinical studies rather than marketing influence doctor prescribing.’’
Monaghan, 2003
(US) [46,47]
Cross-sectional survey 59/108, 55% 3 Students interacted with PSRs on average 10.6 times per month. 40% students
correctly estimated industry marketing expenditures.
Wilkes, 2001
(US) [48]
Cross-sectional survey
(preintervention)
120 3 Every student received at least one gift from industry. 35% felt they were skilled at
critically assessing promotional material.
Sandberg, 1997
(US) [49]
Cross-sectional survey,
multi-institutional
205/205, 100% 0 90% students received $1 book from pharmaceutical company, 25% correctly
recalled the specific company responsible.
Hodges, 1995
(Canada) [50]
Cross-sectional survey 17/21, 81% 3 41% agreed that PSRs had important teaching role. .50% students believed that
PSRs had no impact on prescribing
Weber, 1986
(Canada) [51]
Cross-sectional survey 28/28, 100% 2 In estimating the cost of treatment regimens, medical students were most likely to
correctly estimate (40%) or underestimate (40%) the actual cost
Palmisano,
1980 (US) [52]
Cross-sectional survey
(preintervention)
100 1 85% believed it was improper for a public official to accept a gift; 46% reported it
was improper for a medical students to do so (chi-squared, 2 df=16.94, p,0.0001)
Studies including
both preclinical and
clinical students
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meals from industry was appropriate (82% versus 67%, p,0.001)
[35]. As with all correlational studies, these data cannot
demonstrate causation. A study of medical students, physicians,
and other health professionals found a relationship between the
number of gifts received and the belief that sales representatives do
not influence prescribing (rs=0.24; p,0.04) [50], although this
comes from one of the older studies in our sample and data specific
to the medical student subgroup were not provided. Only one
study found no relationship between students’ total number of
previous contacts with PSRs and perception of the educational
value of PSR interactions (ANOVA p=0.08) [44].
Students in different learning environments had significant
differences in their reported attitudes [35,37,43,53] with perspec-
tives generally consistent with the policies of their schools. One
randomized controlled trial exposed students to small promotional
items and found differences in implicit attitudes between fourth-
year students at two different schools that differed in the strength
of their institutional policies regarding industry access [37]. In one
national sample, the subset of students participating in clinical
clerkships at hospitals that restricted direct industry marketing had
less exposure to industry, according to mean exposure index (a
measure of number of interactions experienced during a month of
clerkship; 2.5 versus 4.6; p,0.001). On a skepticism scale derived
from six of the survey questions (range, 0–1; mean skepticism
score=0.43), these students also displayed a significantly higher
level of skepticism about marketing messages (mean skepticism
score 0.45 versus 0.43; p=0.03) [43]. A separate study found
significant differences in attitudes regarding pharmaceutical
marketing between students at two medical schools (mean
skepticism score 0.55 versus 0.42; p,0.001) and attributed this
divergence to the presence of restrictive policies present at one of
the schools (with more skeptical attitudes expressed by these
students) [37]. After a national reform limiting pharmaceutical
marketing in clinical settings, the percentage of Finnish medical
students who believed that marketing would influence their future
clinical decisions decreased significantly [53].
Attitudes on Reform
In the studies we identified, students generally did not support
excluding sales representatives [31,32,37,43,46,47] or industry
presentations [35] from the learning environment. Student opinions
were split on whether physician–industry interactions should be
regulated by medical schools or the government; surveys from Italy
and Kuwait reported more support for rule-setting than a US study
[32,54,56]. Eighty-six percent of American medical students
reported that during their residencies they would like to interact
with PSRs (86%) [48], and two Finnish surveys [53,57] found that
24%–57% of students wanted more industry-sponsored education.
Faculty disclosure of conflicts of interest before lecturing was
endorsed by 69%–77% of students across all studies [31,35].
Most medical students reported not feeling adequately educated
on physician–industry interactions [43,46,47,53,54,56] with 62%–
86% requesting more instruction in this area [31,35,43,53,54].
First Author,
Year (Country)
Primary
Methodology
Response
Rate
Quality
Rating
(out of 5)
a Main Findings
Vuorenkoski, 2008
(Finland) [53]
Cross-sectional survey,
multi-institutional
1,523/,2,700,
57%
5 17% clinical and 1% preclinical attended $2 PSR presentations per month.
Industry-sponsored education was one source for learning.
Fabbri, 2008
(Italy) [54]
Cross-sectional survey 190/190, 100% 3 71% said that interaction with or gifts from PSR influenced a doctor, but only 24%
said it affected their own behavior.
Fitz, 2007
(US) [55]
Cross-sectional survey,
multi-institutional
667/DNP, 20%–
80%
b
4 28% of preclinical and 65% clinical students thought it was appropriate to accept
gift (p,0.001). Level of knowledge about drug development was same for both
groups.
Hyman, 2007
(US) [56]
Cross-sectional survey 418/723, 58% 3 18% believed that curriculum should include industry-sponsored events; 61% felt
insufficiently educated on interactions with industry.
Vainiomaki, 2004
(Finland) [57]
Cross-sectional survey,
multi-institutional
952/2,800, 34% 4 20% preclinical and 68% clinical students attended $2 PSR presentations per
month. Pharmaceutical industry was identified as one source for learning.
Bellin, 2004
(US) [58]
Cross-sectional survey 221/281, 79% 3 Clinical students had significantly higher exposure to industry than preclinical for
most types of interactions. Contact was most frequent in internal medicine
setting.
Barfett, 2004
(Canada)
c [59]
Cross-sectional survey 202/372, 54% 3 Students found inexpensive gifts more acceptable. No difference was noted in
attitudes by level of training.
Barry, 2000
(US)
c [60]
Cross-sectional survey 208/528, 39% 3 For the scenario of a pharmaceutical company paying a physician for each patient
enrolled in a clinical research project, approximately 22% students chose the most
appropriate professional behavior
Mantyranta, 1995
(Finland)
c [61]
Cross-sectional survey 126/161, 78% 1 70% students supported marketing of drugs; 48% supported existence of
industry-sponsored social events
Barnes, 1971
(US) [62]
Cross-sectional survey 254
b 2 70% supported no longer soliciting industry support for social activities.
Acceptance of promotion increased with more training (no p-value).
Response rate or number of participants was calculated if number not provided in article. A label of ‘‘multi-institutional’’ indicates studies that included students from
more than one medical school or hospital.
aRating based on a 5-point scale developed by Glaser and Bero [28].
bNumber of potential participants and overall response rate were not reported.
cThese studies included preclinical and clinical medical students in their study, but did not present any data separately to allow for comparison between these two
groups.
DNP, did not provide; N/A, not applicable.
doi:10.1371/journal.pmed.1001037.t001
Table 1. Cont.
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on the topic, only 11% of preclinical students reported that the
amount of instruction they received was sufficient [53].
Other Pharmaceutical Policy Issues
The pharmaceutical industry was identified as one source of
information used by students to learn about therapeutics (16%–
49%) [46,47,53,57]. But in one study, students who had interacted
with a PSR reported that side effects, interactions, and contra-
indications of the promoted therapy were either not discussed or
inadequately covered in these encounters [41].
Medical students reported little knowledge of drug costs or
spending on pharmaceutical marketing [38,45,46,47,55], except in
one survey of Italian medical students, in which 62% were
knowledgeable [54]. Two surveys found no change in knowledge
about these areas over the course of undergraduate medical
training [54,55]. When asked to estimate the actual cost of
treatment described in six clinical scenarios, students under-
estimated the actual cost in 40% cases, which was similar to the
responses of residents or attending physicians [51]. However, this
study had methodological flaws and was conducted in 1986; we
did not locate more recent studies to confirm this observation.
One study found that knowledge regarding generic medications
was poor overall [42]. Students reported negative attitudes about
generic drugs, with nearly all agreeing that they were less effective
(95%) and of inferior quality (94%), and caused more side effects
(93%) than branded drugs. However, in another study evaluating
behavior, students from Bahrain tended to prescribe drugs more
frequently using their generic name [33].
Sensitivity Analysis
The oldest [34,49–52,61,62] and lowest-quality studies [38,45,
49,51,52,61,62]—a total of 9 studies—amounted to a total of 8
data points in our analysis (4.2% of the total number of data
points). These data were used for supportive purposes only and the
results of these studies are not included in Tables 2 and 3.
Discussion
This comprehensive systematic review of medical students’
interactions with the pharmaceutical industry found that students
are frequently exposed to pharmaceutical marketing, even in the
preclinical years when learning is mostly done in the classroom
setting. However, we also found that the extent of students’ contact
with industry is associated with positive attitudes about marketing
and skepticism about any negative implications of these interac-
tions. These findings are compatible with the results of a more
limited review [64] that examined PubMed-listed English
language studies of medical student surveys related to pharma-
ceutical industry marketing. The year of training and the presence
of policies restricting drug industry interactions with trainees
appear to influence students’ attitudes about the role of marketing
and other important pharmaceutical policy issues.
Students’ opinions about the pharmaceutical industry differed
between the preclinical and clinical years. Compared with
preclinical students, those in their clinical years reported more
educational value in industry-provided material [31,32,35,41,44,
46–48,50] and were more accepting of gifts from industry
[37,43,48,52,54,55,56]—both to themselves and to professional
physicians [31,32,55,56]. Long hours spent working and studying
and increasing financial hardship [65] may have contributed to
these feelings of entitlement. Preclinical students were less likely to
feel sufficiently educated on the topic of physician–industry
interactions with the pharmaceutical industry [53,56], though
confidence on this topic was also uncommon among clinical
students [43,46,47,53,54,56].
Some evidence showed that student opinions varied by medical
school and the extent of industry interactions in those commu-
Table 2. Exposures of medical students to the pharmaceutical industry.
Type of Exposure
Percentage of Preclinical Students
Reporting Interaction
a Percentage of Clinical Students Reporting Interaction
a
Any interaction 61% [32]; 91% [30]; 97% [58] 74% [35]; 100% [48]; 100% [58]; 1/week (since start of clerkship) [43]
Interaction with PSRs 40% [55]; 64% [30]; 1% (at least 2/month)
[53]; 20% (at least 2/month) [57]
95% [44]; .80% [55]; 17% (at least 2/month) [53]; 68% (at least 2/month) [57]; 10.6/month
[46,47]
Industry-sponsored
educational events
0% (at least 2/month) [53]; 7%
(at least 2/month) [57]
3% (at least 2/month) [53]; 22% (at least 2/month) [57]; 26% (since start of clerkship) [43]
Gifts ,40% [55] 80% [55]
N Fine dining or dinner 35% [48]; 51% [43]
N Other food 4% [32]; 11% (1st years) [31]; 53%
(2nd years) [31]; 90% [58]
90% [41]
b; 98% [58]; 89% (snack, since start of clerkship) [43]; 97% (lunch, since start of
clerkship) [43]
N Noneducational gift
(pen, mug)
18% (1st years) [31]; 57% (2nd years)
[31]; 34% [32]; 63% [58]
44% [41]
b; 92% [58]; 94% (since start of clerkship) [43]; 95% [48]
N Textbook/educational
material
11% [32]; 11% (textbook) [58]; 30%
(pocket text) [58]
26% (textbook) [58]; 51% (since start of clerkship) [43]; 68% [48]; 79% (pocket text) [58]; 87%
[41]
b
N Journal reprint/glossy
handout
4% (1st years) [31]; 46% (2nd years)
[31]; 42% [32]; 14% [59]
90% (since start of clerkship) [43]; 14% [59]
N Drug sample 1% (1st years) [31]; 11% (2nd years)
[31]; 25% [32]
23% (during last year) [40]; 41% [38]
b; 42% (since start of clerkship) [43]; 43% [48]
N Social event 5% [32] 34% (since start of clerkship) [43]
Each entry reports data on exposure of preclinical and clinical medical students from the studies included in our sample. Data from studies performed before 2000 or
those that received a score of 0–2 on the Glaser-Bero scale are not included [34,38,45,49–52,61,62].
aData indicate students reporting at least one interaction during medical school (unless otherwise specified).
bStudy sample derived from students who had at least one interaction with PSR and reported on one such interaction.
doi:10.1371/journal.pmed.1001037.t002
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Statements Describing Physician–Industry Interactions
Data Relating Agreement of
Preclinical Students with
Statements
Data Relating Agreement of Clinical
Students with Statements
Topic Statements
General
information/promotion
Is useful to learn about drugs 29% [31]; 62% [32] 53% [37]; 65% [37]; 71% [43]
Has educational value 66% [35]; 49% [48]
Influences own prescribing 11% [53]; 19% [57] 12% [53]; 25% [57]
Does not influence own prescribing LS 3.0 out of 5 [30] 74% [35]
Is unethical 29% [32] —
Pharmaceutical sales
representatives
Feel PSRs should be excluded from learning
environment
29% [31]; 26% [32] 67% [37]; 18% [37]; 17% [43]; LS 1.6
out of 5 [46,47]
Desire more interaction with PSRs 35% [57]; 40% [53] 24% [57]; 35% [53]
Feel PSRs have important teaching role 39% [32] LS 2.8 out of 5 [46,47]
Have educational value, or impart useful
and accurate information
LS 2.6 out of 5 [30] 22% [44]; 4.2 out of 10 [41]; LS 3.1
out of 5 [46,47]
Are biased — 87% [44]
Provide trustworthy information 21% [32] —
Influence physician prescribing LS 3.4 out of 5 [30] 44% [44]
Do not influence own prescribing — LS 2.8 out of 5 [46,47]
Are bad for patients LS 3.0 out of 5 [30] —
Industry-supported grand
rounds/educational presentations
Are biased 74% [32] 92% [37]; 68% [37]; 67% [43]
Are useful/helpful/educational 36% [32] 52% [37]; 86% [37]; 89% [43]
Desire more 46% [57]; 51% [53] 57% [57]; 56% [53]
Should not be allowed — 45% [35]
Gifts Given to students
Are appropriate to accept 28% [55]; LS 1.7 out of 5 [56] 65% [55]; LS 1.5 out of 5 [56]
Have minimal influence 34% [31]; 45% [32] 30% [37]; 61% [37]; 71% [43]
Support because of minimal income 48% [31] 52% [37]; 74% [37]; 80% [43]
Should not be restricted — 24%–28% [44]
Given to physicians
Are appropriate 30% [55] .50% [55]
Are inappropriate/unethical — 3%–26% [48]
Are inappropriate for government official 85% [55] 84% [55]
Influence prescribing
Own 24% [31]; 33% [32] 63% [37]; 29% [37]; 31% [43]
Other student 39% [31] 69% [37]; 38% [37]; 42% [43]
Physician — 13%–18% [48]
Do not influence physician prescribing 70% [55] 72% [55]
Do not influence own prescribing — LS 3.5 out of 5 [46,47]
Drug Samples Support because go to uninsured/needy LS 3.4 out of 5 [30] 88% [40]
Education Educated adequately on
interactions with industry
11% [53]; LS 1.2 out of 5 [56] LS 2.6 out of 5[46,47]; 39% [53]; LS 1.7
out of 5 [56]
Believe not sufficiently educated on
interactions with industry
89% [53] 61% [53]; 83% [43]
Feel competent to navigate interactions — 41% [35]
Desire more education 77%–79% [31]; 66% [53] 86% [35]; 78% [43]; 62% [53]
Disclosure Support prelecture disclosure of
potential conflicts
69% [31] 77% [35]
Faculty relationships
with industry
Agree not ethical to receive research funds — 12% [48]
Agree not ethical to receive honoraria
for lecturing
— 11%–12% [48]
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policies limiting interactions with PSRs expressed significantly
more critical views of industry than the other students surveyed,
though it is not clear whether self-selection played a role [43].
Similar differences were found by Grande et al., with clinical
students at the school with a strong policy regarding student-
industry interactions differing in their attitudes with students at a
school without a strong policy and as compared to the findings of
Sierles et al. [37]. Few studies rigorously evaluate whether
observed changes in attitude over the course of medical or among
different learning environments are causal or simply correlational;
this represents a significant limitation of the current literature.
Why would attitudes change over the course of medical
education, or why do they differ between two groups of clinical
students at different schools? One possible explanation is that
industry representatives are effective in directly molding medical
students’ attitudes about these issues. Another possibility is that the
characteristics of medical students’ learning environments shape
attitudes about the pharmaceutical industry. The implicit lessons
communicated through institutional policies and role models have
been described as the ‘‘hidden curriculum’’ by scholars of learning
theory [66,67]. The importance of role modeling is explicitly
recognized, as students reported ‘‘examples from medical teachers’’
as one important influence on their prescribing decisions [36]. This
socialization process has been implicated in other attitudinal
changes seen over the course of medical training, such as cynicism
[68], burnout [69], and lack of interest in primary care [70].
A number of features of medical education may potentiate these
educational cues. First, students are rapidly developing a
professional identity and forming a foundation of professional
values, making it likely that they will absorb the norms of their
surroundings in creating these attitudes. Second, their behavior is
constrained by their position at the bottom of the social hierarchy.
For example, one study found that 93% of third-year students had
been asked or required to attend an industry-sponsored lunch by a
superior [43]. This dynamic may help explain why students are
likely to accept gifts from pharmaceutical industry representatives
even if they believe it is inappropriate. Passive adoption of the
norms displayed by role models and actions in contrast to personal
values contribute to the socialization of medical students and may
in turn impact their professional practice.
Medical students’ attitudes in some domains were similar to
those reported by residents and practicing physicians. We found
that students were more approving of small gifts from industry and
those said to have an educational purpose, as compared to large
gifts [30–32,34,35,46,47,54,59,62]. In a prior review, Wazana
observed a similar pattern in residents and physicians [4].
However, other attitudes appeared to evolve over the course of
medical education and practice. For example, more medical
students in our analysis reported believing that gifts influence
prescribing (24%–63%) [31,32,37,43,46–48,54] than did practi-
cing physicians in the Wazana review (8%–13%, Likert scale [LS]
1.6–1.8) [4]. Shifts in attitude that occur during the course of
training may be attributable to clinicians’ greater confidence in
their ability to objectively evaluate scientific evidence and
distinguish credible information from overstatements in marketing
messages. Practicing physicians, however, have been found to be
far less adept at this skill than they report [4,12]. Thus, medical
school may be an optimal time to educate about problematic issues
associated with learning about drugs through pharmaceutical
marketing channels.
Our study has several limitations. Most of the included studies
were cross-sectional surveys, which have typical limitations of
sampling response rate (representativeness and size), and the
difficulty of imputing longitudinal change from cross-sectional
data. The heterogeneity of survey questions made it impossible to
combine results into a formal meta-analysis because of the risk of
false-positive conclusions [71]. Nonetheless, we took steps to
address the limitations of a narrative synthesis, such as introduc-
tion a formal grading system of each study’s methodological
strength. Our sensitivity analysis confirmed that the results
reported are driven by the newest and highest quality studies
identified. Since variability in phrasing of survey questions was
common, we took a conservative approach to categorizing
responses and reporting response ranges. Publication bias could
have also impacted our conclusions.
Since relationships between the pharmaceutical industry and
organized medicine are context dependent, some variability
Statements Describing Physician–Industry Interactions
Data Relating Agreement of
Preclinical Students with
Statements
Data Relating Agreement of Clinical
Students with Statements
Topic Statements
Feel acceptable to receive honoraria
for lecturing
— 18% [35]
Institutional relationships
and policies
Support industry funds to:
Lower tuition 26% [31] 44% [37]; 55% [37]; 54% [43]
Pay for printing (with logo) 33% [31]
Believe adequate separation between teaching
institution and pharmaceutical industry
LS 2.2 out of 5 [56] 81% [35]; LS 1.9 [56]
Support industry-sponsored events in curriculum LS 1.4 out of 5 [56] LS 1.2 out of 5 [56]
Agree should be regulated (by school or
government)
LS 2.7 out of 5 [56]; LS 3.9
out of 5 [30]
LS 2.6 out of 5 [56]
This is a summary of the attitudes of preclinical and clinical medical students from the studies that met inclusion criteria. Likert scale (LS) data were all adjusted to
standard of 1=strongly disagree; 5=strongly agree. For 10-point scales, 10 represents ‘‘very good.’’ Grande et al. [34] presented data for two distinct groups of medical
students. Data from studies performed before 2000, those that received a score of 0–2 on the Glaser-Bero scale [34,38,45,49–52,61,62], and those that did not report
responses separately for preclinical and clinical populations [54,59] in the relevant domains are not included.
doi:10.1371/journal.pmed.1001037.t003
Table 3. Cont.
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captured by analysis of the learning environment. We noted
some cross-cultural similarities and differences in exposures and
attitudes, but none of the included studies were designed
specifically to address this issue and more robust data are
needed. Likewise, some surveys did not account for confounders
within the learning environment that could be important in
shaping students’ exposures and attitudes or secular trends. For
instance, while most studies did not consider gender differences,
one found that women were less willing to accept gifts from
industry [54]. Future longitudinal surveys following individual
trainees could more clearly map the trajectory of beliefs toward
the pharmaceutical industry and related issues over the course
of professional development and determine which character-
istics (institutional, environmental, and personal) most strongly
impact this process.
Despite these limitations, this review of the literature provides
important insights into the nexus between the pharmaceutical
industry and undergraduate medical education and in our view
helps elucidate an agenda for moving forward. Our findings
demonstrate a significant hole in the existing research, most
notably the need for studies that can determine whether changes
in student attitudes toward the pharmaceutical industry are caused
by contact with industry sources, the influence of role models,
institutional policies, or other factors.
Our review also is relevant to those who teach medical students,
including those outside of the US (given the diversity of settings of
the studies analyzed). Strategies to educate students on physician–
industry interactions should directly address misconceptions about
the effects of marketing and other biases that can emerge from
industry interactions. Support for reforms such as prelecture
disclosure of relevant faculty relationships with industry are likely
to be well received by students. However, education alone may be
insufficient if policymakers are not also engaged. Modifiable
institutional characteristics, including rules regulating industry
interactions, can play an important role in shaping students’
attitudes. Interventions that decrease students’ contact with
industry and eliminate gifts may have a positive effect on building
the ‘‘healthy skepticism’’ that evidence-based medical practice
requires. Given the potential for educational and institutional
messages to be counteracted by the hidden curriculum, changes
should be directed at faculty and residents who serve as role
models for medical students. These changes can help move
medical education a step closer to two important goals: the
cultivation of strong professional values, as well as the promotion
of a respect for scientific principles and critical review of evidence
that will later inform clinical decision-making and prescribing
practices.
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Background. The complex relationship between health
professionals and the pharmaceutical industry has long been
a subject of discussion among physicians and policymakers.
There is a growing body of evidence that suggests that
physicians’ interactions with pharmaceutical sales represe-
ntatives may influence clinical decision making in a way that
is not always in the best interests of individual patients, for
example, encouraging the use of expensive treatments that
have no therapeutic advantage over less costly alternatives.
The pharmaceutical industry often uses physician education
as a marketing tool, as in the case of Continuing Medical
Education courses that are designed to drive prescribing
practices.
One reason that physicians may be particularly susceptible
to pharmaceutical industry marketing messages is that
doctors’ attitudes towards the pharmaceutical industry may
form early in their careers. The socialization effect of
professional schooling is strong, and plays a lasting role in
shaping views and behaviors.
Why Was This Study Done? Recently, particularly in the
US, some medical schools have limited students’ and
faculties’ contact with industry, but some have argued that
these restrictions are detrimental to students’ education.
Given the controversy over the pharmaceutical industry’s
role in undergraduate medical training, consolidating current
knowledge in this area may be useful for setting priorities for
changes to educational practices. In this study, the
researchers systematically examined studies of pharmace-
utical industry interactions with medical students and
whether such interactions influenced students’ views on
related topics.
What Did the Researchers Do and Find? The researchers
did a comprehensive literature search using appropriate
search terms for all relevant quantitative and qualitative
studies published before June 2010. Using strict inclusion
criteria, the researchers then selected 48 articles (from 1,603
abstracts) for full review and identified 32 eligible for
analysis—giving a total of approximately 9,850 medical
students studying at 76 medical schools or hospitals.
Most students had some form of interaction with the
pharmaceutical industry but contact increased in the clinical
years, with up to 90% of all clinical students receiving some
form of educational material. The highest level of exposure
occurred in the US. In most studies, the majority of students
in their clinical training years found it ethically permissible
for medical students to accept gifts from drug manufac-
turers, while a smaller percentage of preclinical students
reported such attitudes. Students justified their entitlement
to gifts by citing financial hardship or by asserting that most
other students accepted gifts. In addition, although most
students believed that education from industry sources is
biased, students variably reported that information obtained
from industry sources was useful and a valuable part of their
education.
Almost two-thirds of students reported that they were
immune to bias induced by promotion, gifts, or interactions
with sales representatives but also reported that fellow
medical students or doctors are influenced by such encoun-
ters. Eight studies reported a relationship between exposure
to the pharmaceutical industry and positive attitudes about
industry interactions and marketing strategies (although not
all included supportive statistical data). Finally, student
opinions were split on whether physician–industry interac-
tions should be regulated by medical schools or the
government.
What Do These Findings Mean? This analysis shows that
studentsarefrequentlyexposedtopharmaceuticalmarketing,
even in the preclinical years, and that the extent of students’
contact with industry is generally associated with positive
attitudes about marketing and skepticism towards any
negative implications of interactions with industry.
Therefore, strategies to educate students about interactions
with the pharmaceutical industry should directly address
widely held misconceptions about the effects of marketing
and other biases that can emerge from industry interactions.
But education alone may be insufficient. Institutional policies,
such as rules regulating industry interactions, can play an
important role in shaping students’ attitudes, and interven-
tions that decrease students’ contact with industry and
eliminate gifts may have a positive effect on building the
skills that evidence-based medical practice requires. These
changes can help cultivate strong professional values and
instill in students a respect for scientific principles and critical
evidence review that will later inform clinical decision-making
and prescribing practices.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001037.
N Further information about the influence of the pharma-
ceutical industry on doctors and medical students can be
found at the American Medical Students Association
PharmFree campaign and PharmFree Scorecard, Medsin-
UK’s PharmAware campaign, the nonprofit organization
Healthy Skepticism, and the Web site of No Free Lunch.
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